Our Services
Medical Information
Helpful Resources
Published on: 9/28/2026
Yes, MiraLAX (polyethylene glycol 3350) is a laxative, specifically an osmotic laxative that draws water into the colon to soften stool and make bowel movements easier, typically working within 1 to 3 days. Stimulant laxatives such as bisacodyl (Dulcolax) or senna work differently by triggering intestinal muscle contractions to push stool along, often producing results in 6 to 12 hours but with a higher chance of cramping, urgency, and dependence with prolonged use. Because MiraLAX does not stimulate the bowel wall, it is generally considered gentler and is often recommended for longer-term or occasional constipation relief, while stimulants are usually reserved for short-term use. Dosage, timing, hydration, and underlying causes of constipation all affect which option is appropriate, and certain symptoms like blood in stool, severe pain, or vomiting signal a need for medical care rather than an over-the-counter product. There are several important distinctions and safety considerations to weigh, so see below to understand more before choosing.
Constipation can stem from diet, medication side effects, dehydration, thyroid problems, pelvic floor dysfunction, or other conditions, which means the right laxative depends on what is actually driving your symptoms. Rather than guessing between an osmotic and a stimulant option, it helps to get a clearer picture of the underlying cause first. You can take a free, instant, online symptom check to review your symptoms, see possible explanations, and get guidance on whether self-care is reasonable or whether you should speak with a clinician. It takes only a few minutes and can help you approach next steps with far more confidence.
Last reviewed for medical accuracy: 09/28/2026
Constipation is a common issue affecting people of all ages. You may have heard of MiraLAX and wondered, “is miralax a laxative?” The short answer is yes—MiraLAX is classified as an osmotic laxative. Below, we’ll explain how MiraLAX works, how it differs from stimulant laxatives, and when you might choose one type over another.
MiraLAX is an over-the-counter (OTC) medication whose active ingredient is polyethylene glycol 3350 (PEG 3350). Unlike stimulant laxatives that trigger contractions in your intestines, MiraLAX works gently to draw water into the colon. This extra water softens stool and makes bowel movements easier without forcing the intestines to squeeze.
Key points about MiraLAX:
Osmotic laxatives like MiraLAX pull water from the body’s surrounding tissues into the colon. The increased water content:
Advantages of osmotic laxatives:
Stimulant laxatives prompt the intestine walls to contract, pushing stool through more quickly. Common stimulant laxatives include senna (Senokot®) and bisacodyl (Dulcolax®).
Characteristics of stimulant laxatives:
| Feature | MiraLAX (Osmotic) | Stimulant Laxatives |
|---|---|---|
| Mechanism | Draws water into colon | Stimulates intestinal nerves |
| Typical onset | 1–3 days | 6–12 hours (oral) |
| Cramping/urgency risk | Low | Moderate to high |
| Dependency risk | Low | Higher with prolonged use |
| Ideal use | Occasional, gentle relief | Short-term, quick relief |
| Long-term safety | Generally safe under doctor care | Not recommended for chronic use |
You might opt for MiraLAX if you:
Stimulant laxatives may be prescribed or recommended when:
Both osmotic and stimulant laxatives are considered safe when used as directed, but you should be aware of potential side effects and precautions.
Common side effects of MiraLAX:
Common side effects of stimulant laxatives:
General precautions:
Constipation can occasionally signal a more serious issue. Contact a healthcare professional if you experience:
For a free, online symptom check, you may consider using the doctor approved Ubie Symptom Checker.
While MiraLAX is a safe and effective osmotic laxative for most people, it’s important to tailor any treatment to your individual needs. Speak to a doctor about:
If you suspect a life-threatening condition or experience alarming symptoms, seek immediate medical attention.
(References)
* Liu LW. Chronic constipation: current treatment options. Can J Gastroenterol. 2011 Oct;25 Suppl B(Suppl B):22B-28B. PMID: 22114754; PMCID: PMC3206558.
* Sera L, McPherson ML. Management of Opioid-Induced Constipation in Hospice Patients. Am J Hosp Palliat Care. 2018 Feb;35(2):330-335. doi: 10.1177/1049909117705379. Epub 2017 Apr 20. PMID: 28423917.
* Han D, Iragorri N, Clement F, Lorenzetti D, Spackman E. Cost Effectiveness of Treatments for Chronic Constipation: A Systematic Review. Pharmacoeconomics. 2018 Apr;36(4):435-449. doi: 10.1007/s40273-018-0609-6. PMID: 29352437.
* Jang HJ, Chung JY, Seo JH, Moon JS, Choe BH, Shim JO. Nationwide Survey for Application of ROME IV Criteria and Clinical Practice for Functional Constipation in Children. J Korean Med Sci. 2019 Jul 8;34(26):e183. doi: 10.3346/jkms.2019.34.e183. Epub 2019 Jul 8. PMID: 31269544; PMCID: PMC6609424.
* Drugs for Irritable Bowel Syndrome. Med Lett Drugs Ther. 2020 Mar 23;62(1594):25-32. PMID: 32324172.
* Grupo de Trabajo de Constipación del Comité Nacional de Gastroenterología Pediátrica. [Functional constipation in pediatrics, diagnosis and treatment]. Arch Argent Pediatr. 2021 Feb;119(1):s39-s47. doi: 10.5546/aap.2021.s39. PMID: 33459004.
* Chang L, Chey WD, Imdad A, Almario CV, Bharucha AE, Diem S, Greer KB, Hanson B, Harris LA, Ko C, Murad MH, Patel A, Shah ED, Lembo AJ, Sultan S. American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. Am J Gastroenterol. 2023 Jun 1;118(6):936-954. doi: 10.14309/ajg.0000000000002227. Epub 2023 May 19. PMID: 37204227; PMCID: PMC10544839.
* Kistemaker KRJ, Sijani F, Brinkman DJ, de Graeff A, Burchell GL, Steegers MAH, van Zuylen L. Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis. Cancer Treat Rev. 2024 Apr;125:102704. doi: 10.1016/j.ctrv.2024.102704. Epub 2024 Mar 1. PMID: 38452708.
* Gordon M, Grafton-Clarke C, Rajindrajith S, Benninga MA, Sinopoulou V, Akobeng AK. Treatments for intractable constipation in childhood. Cochrane Database Syst Rev. 2024 Jun 19;6(6):CD014580. doi: 10.1002/14651858.CD014580.pub2. Epub 2024 Jun 19. PMID: 38895907; PMCID: PMC11190639.
* Pan Y, Jiao FY. Addressing functional constipation in children: A call for comprehensive and collaborative management. World J Gastroenterol. 2025 Feb 21;31(7):98889. doi: 10.3748/wjg.v31.i7.98889. PMID: 39991672; PMCID: PMC11755255.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.